Should_all_patients_with_node-negative_breast_cancer_receive_adjuvant_therapy?_Identifying_additional_subsets_of_low-risk_patients_who_are_highly_curable_by_surgery_alone._This_study,_which_used_combined_first-generation_prognostic_factors_(tumor_size,_histologic_differentiation,_and_age)_on_408_patients_with_axillary_node-negative_(ANN)_breast_cancer_treated_by_surgery_alone_without_systemic_adjuvant_therapy_between_1976_and_1987_at_the_Roswell_Park_Cancer_Institute,_discerned_four_subsets_of_low-risk_patients_with_a_7-year_relapse_rate_of_6%_or_better._The_first_subset_consisted_of_48_patients_(12%_of_the_population)_with_tumors_1_cm_or_less_in_diameter_that_were_well_or_moderately_differentiated._These_patients_had_a_disease-free_rate_(DFR)_of_100%_(95%_confidence_interval_CI,_94%_to_100%)._The_second_subset_consisted_of_35_patients_(9%_of_the_population)_with_tumors_less_than_or_equal_to_1_cm_that_were_poorly_differentiated_or_anaplastic._These_patients_older_than_50_years_of_age_had_a_DFR_of_97%_(95%_CI,_91%_to_100%)._The_third_subset_consisted_of_36_patients_(9%_of_the_population)_with_tumors_1.1_to_2_cm_that_were_well_or_moderately_differentiated._These_patients_were_older_than_50_years_of_age_and_had_a_DFR_of_94%_(95%_CI,_85%_to_100%)._The_fourth_subset_consisted_of_36_patients_with_ductal_carcinoma_in_situ_with_microscopic_invasion._These_patients_had_a_DFR_of_100%_(95%_CI,_87%_to_100%)._Twenty-two_of_these_patients,_not_in_the_other_subsets_mentioned,_comprised_5%_of_the_total_population._These_patients_at_low_risk_of_recurrence,_who_comprise_one_third_of_the_entire_node-negative_population,_are_highly_curable_by_local_therapy_alone_and_may_be_spared_the_risks_and_costs_of_routine_adjuvant_systemic_therapy_(AST)._Patients_with_tumors_larger_than_2_cm_(152_patients;_37%_of_the_population)_are_at_high_risk_of_recurrence_(26%_with_a_DFR_of_74%_95%_CI,_64%_to_84%)_and_should_routinely_receive_systemic_adjuvant_therapy._Patients_with_tumors_up_to_2_cm_who_are_not_in_the_low-risk_groups_fall_in_a_gray_area_(recurrence,_15%_to_21%;_DFR,_79%_to_85%)._For_these_groups,_combining_second-generation_prognostic_factors_such_as_DNA_ploidy,_S-phase_fraction,_or_cathepsin_D_should_give_the_physician_additional_information_to_aid_in_making_decisions_regarding_adjuvant_therapy.